Cardiovascular Inflammation Reduction Trial (CIRT)
A randomized, double-blind, placebo-controlled, event-driven trial of weekly low-dose methotrexate (LDM) in the prevention of cardiovascular events among stable coronary artery disease patients with Type 2 Diabetes or Metabolic Syndrome.
The Cardiovascular Inflammation Reduction Trial (CIRT) is a randomized clinical trial investigating whether taking low-dose methotrexate reduces heart attacks, strokes, or death in people with Type 2 diabetes or metabolic syndrome that have had a heart attack or multiple coronary blockages. This trial is funded by the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH).
Learn More
We appreciate your interest in joining a medical clinical trial. Please note that not all who apply are accepted into a trial.
Menu
Newsletter
Sign up with your name and email address to obtain ongoing updates. Please know that you can ‘opt out’ at any time.
Thanks for subscribing! Please check your email for further instructions to confirm your subscription.